Pictet Asset Management
ITCI

Pictet Asset Management’s Intra-Cellular Therapies Inc. ITCI Stock Holding History

Pictet Asset Management’s Portfolio ITCI Stock Details ITCI Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q2 		– Sell
-41,041
Closed -$5.41M – 2077
2025
Q1 		$5.41M Sell
41,041
-1,499,444
-97% -$187M 0.01% 784
2024
Q4 		$129M Sell
1,540,485
-78,783
-5% -$6.47M 0.14% 172
2024
Q3 		$118M Buy
1,619,268
+364,192
+29% +$27.4M 0.13% 179
2024
Q2 		$86M Buy
1,255,076
+434,546
+53% +$30.1M 0.1% 211
2024
Q1 		$56.8M Sell
820,530
-514,213
-39% -$35.3M 0.06% 285
2023
Q4 		$95.6M Sell
1,334,743
-412,917
-24% -$23.8M 0.11% 207
2023
Q3 		$91M Buy
+1,747,660
New +$102M 0.11% 204

Other funds holding ITCI

DekaBank Deutsche Girozentrale
DekaBank Deutsche Girozentrale Frankfurt, Germany $60.6B AUM 23.27% 1-Year Est. Return
Osaic Holdings
Osaic Holdings Scottsdale, Arizona $68.3B AUM 20.5% 1-Year Est. Return
KIM
Kestra Investment Management Austin, Texas $5.8B AUM 14.71% 1-Year Est. Return
HNB
Huntington National Bank Columbus, Ohio $18.1B AUM 24.69% 1-Year Est. Return

Pictet Asset Management's ITCI Position: Q2 2025 in Review

Pictet Asset Management sold out of Intra-Cellular Therapies Inc. (ITCI) in Q2 2025, closing a stake of 41,041 shares — an estimated $5.41M sold.

Pictet Asset Management first reported a position in ITCI in Q3 2023 and held it in 7 quarters. The position peaked at $129M in Q4 2024. 4 funds tracked by Wall St. Rank hold ITCI as of Q2 2025.

  • Pictet Asset Management reported no remaining Intra-Cellular Therapies Inc. position as of Q2 2025 after selling out during the quarter.
  • Pictet Asset Management sold 41,041 Intra-Cellular Therapies Inc. shares in Q2 2025, an estimated $5.41M.
  • Pictet Asset Management first reported a position in Intra-Cellular Therapies Inc. in Q3 2023 and held it in 7 quarters.
  • Pictet Asset Management's Intra-Cellular Therapies Inc. position peaked at $129M in Q4 2024.
  • 4 funds tracked by Wall St. Rank held Intra-Cellular Therapies Inc. as of Q2 2025.

Based on Pictet Asset Management's 13F filing for Q2 2025, filed 13 Aug 2025.